Improving Treatment Success Rates for Type 2 Diabetes: Recommendations for a Changing Environment

被引:0
|
作者
Triplitt, Curtis [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78207 USA
[2] Texas Diabet Inst, San Antonio, TX USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2010年 / 16卷 / 07期
关键词
INITIAL COMBINATION THERAPY; SITAGLIPTIN; METFORMIN; ADHERENCE; INSULIN; ACHIEVEMENT; EXENATIDE; EFFICACY; SAFETY; ADULTS;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
As demonstrated by suboptimal levels of therapeutic goal achievement, there exists significant room for improvement in type 2 diabetes management. Despite widespread disease awareness and high rates of risk-factor testing in managed care, effective metabolic control in patients with type 2 diabetes is lacking and points toward a phenomenon known as clinical inertia. Clinical inertia, defined as a failure to initiate or advance therapy in a patient who is not at the evidence-based goal, is a key contributing factor in the suboptimal rates of therapeutic target achievement for type 2 diabetes. The causes of clinical inertia are multifactorial and interactive, arising among patients, providers, and health systems and from specific characteristics of available treatments. Therapeutic nonadherence is perhaps the most significant factor contributing to clinical inertia, with recent analyses demonstrating that providers are more likely to prescribe a dose escalation in patients who are adherent to therapy compared with those who are not. While the concept may be counterintuitive, antihyperglycemic agents also have the potential to cause or contribute to the phenomenon of clinical inertia. This often occurs via factors inherent to the drugs themselves, such as treatment-related adverse effects (eg, hypoglycemia, weight gain, edema, gastrointestinal symptoms), perception of long-term safety profiles, and the complexity of the treatment regimen. Often not considered, but equally important, is the durability of an antihyperglycemic agent to maintain glycosylated hemoglobin (A1C) level goals. Because no monotherapy exists to arrest the pancreatic beta-cell failure of type 2 diabetes, early combination therapy with thiazolidinediones and glucagon-like protein-1 agonists that is associated with sustained A1C level reduction is the only hope to change the progressive nature of type 2 diabetes mellitus. (Am J Manag Care. 2010; 16: S195-S200)
引用
收藏
页码:S195 / S200
页数:6
相关论文
共 50 条
  • [1] Improving Rates of Monitoring for Type 2 Diabetes Complications
    Singh, Puja
    Wolfgram, Peter
    [J]. DIABETES, 2020, 69
  • [2] Changing the Treatment Paradigm for Type 2 Diabetes
    Del Prato, Stefano
    Penno, Giuseppe
    Miccoli, Roberto
    [J]. DIABETES CARE, 2009, 32 : S217 - S222
  • [3] Changing targets in the treatment of type 2 diabetes
    Massi-Benedetti, Massimo
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 : S5 - S13
  • [4] Improving Rice Zinc Biofortification Success Rates Through Genetic and Crop Management Approaches in a Changing Environment
    Nakandalage, Niluka
    Nicolas, Marc
    Norton, Robert M.
    Hirotsu, Naoki
    Milham, Paul J.
    Seneweera, Saman
    [J]. FRONTIERS IN PLANT SCIENCE, 2016, 7
  • [5] RECOMMENDATIONS FOR THE PHARMACOLOGIC TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES
    Menendez Torre, E.
    Lafita Tejedor, J.
    Artola Menendez, S.
    Millan Nunez-Cortes, J.
    Alonso Garcia, A.
    Puig Domingo, M.
    Garcia Solans, J. R.
    Alvarez Guisasola, F.
    Garcia Alegria, J.
    Mediavilla Bravo, J.
    Miranda Fernandez-Santos, C.
    Romero Gonzalez, R.
    [J]. FARMACEUTICOS COMUNITARIOS, 2010, 2 (04): : 154 - 161
  • [6] Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes
    Menendez Torre, E.
    Lafita Tejedor, J.
    Artola Menendez, S.
    Millan Nunez-Cortes, J.
    Alonso Garcia, A.
    Puig Domingo, M.
    Garcia Solans, J. R.
    Alvarez Guisasola, F.
    Garcia Alegria, J.
    Mediavilla Bravo, J.
    Miranda Fernandez-Santos, C.
    Romero Gonzalez, R.
    [J]. AVANCES EN DIABETOLOGIA, 2010, 26 (05): : 331 - 338
  • [7] The changing food environment and neighborhood prevalence of type 2 diabetes
    Zick, Cathleen D.
    Curtis, David S.
    Meeks, Huong
    Smith, Ken R.
    Brown, Barbara B.
    Kole, Kyle
    Kowaleski-Jones, Lori
    [J]. SSM-POPULATION HEALTH, 2023, 21
  • [8] Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes
    Menendez Torre, E.
    Lafita Tejedor, J.
    Artola Menendez, S.
    Milian Nunez-Cortes, J.
    Alonso Garcia, A.
    Puig Domingo, M.
    Garcia Solans, J. R.
    Alvarez Guisasola, F.
    Garcia Alegria, J.
    Mediavilla Bravo, J.
    Miranda Fernandez-Santos, C.
    Romero Gonzalez, R.
    [J]. REVISTA CLINICA ESPANOLA, 2011, 211 (03): : 147 - 155
  • [9] Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes
    Menendez Torre, Edelmiro
    Lafita Tejedor, Francisco Javier
    Artola Menendez, Sara
    Millan Nunez-Cortes, Jesus
    Alonso Garcia, Angeles
    Puig Domingo, Manuel
    Garcia Solans, Jose Ramon
    Alvarez Guisasola, Fernando
    Garcia Alegria, Javier
    Mediavilla Bravo, Javier
    Miranda Fernandez-Santos, Carlos
    Romero Gonzalez, Ramon
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2011, 23 (01): : 40 - 48
  • [10] Changing Patterns in the Treatment of Type 2 Diabetes Introduction
    Pratley, Richard E.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2013, 126 (09): : S1 - S1